CureVac N.V. (CVAC): Price and Financial Metrics Recent IPO


CureVac N.V. (CVAC) Recent IPO

Today's Latest Price: $103.23 USD

2.88 (2.87%)

Updated Jan 19 4:00pm

Add CVAC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

CVAC Stock Price Chart Interactive Chart >

Price chart for CVAC

CVAC Price/Volume Stats

Current price $103.23 52-week high $151.80
Prev. close $100.35 52-week low $36.15
Day low $100.50 Volume 403,600
Day high $106.72 Avg. volume 460,755
50-day MA $93.97 Dividend yield N/A
200-day MA $0.00 Market Cap 18.17B

CureVac N.V. (CVAC) Company Bio


CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.


CVAC Latest News Stream


Event/Time News Detail
Loading, please wait...

CVAC Latest Social Stream


Loading social stream, please wait...

View Full CVAC Social Stream

Latest CVAC News From Around the Web

Below are the latest news stories about CureVac NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

Bayer aims to help CureVac with COVID-19 vaccine output, says CEO

German pharmaceutical giant Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday. "We are prepared to pull out all the stops for this," Werner Baumann told the Welt am Sonntag newspaper. "This is not primarily about financial considerations but about making the vaccine available as quickly as possible."

Yahoo | January 17, 2021

CureVac: Smart Money Is On COVID-19 Vaccine Approval

Investment Thesis The global COVID-19 vaccine rollout has begun in earnest, and so far - in the Western world at least - its three developers - Moderna (MRNA), Pfizer (PFE)/BioNTech (BNTX) and AstraZeneca (AZN), are shouldering all of the distribution burden. Pfizer / BioNTech and Moderna's messenger-RNA derived vaccines have...

Edmund Ingham on Seeking Alpha | January 15, 2021

Vaccine Stocks May Be Overvalued Due To The Coming Vaccine Glut

Stocks of the developers of corona vaccines have been among last year's top performers. Moderna (MRNA), for example, at its peak in early December had jumped as much as 800% and added a stunning $50bn in market capitalization. Similarly. Pfizer (PFE) added about $40 bn, while its partner BioNTech (BNTX)...

Thomas Kirchner on Seeking Alpha | January 13, 2021

Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY

The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.

Yahoo | January 13, 2021

mRNA Vaccines Could Vanquish Covid Today, Cancer Tomorrow

(Bloomberg Opinion) -- The night is darkest just before dawn, they say. Dark it certainly is right now. The more contagious variants of SARS-CoV-2 coming out of the U.K. and South Africa will make the pandemic worse before mass vaccination can make it better.But take another look at some of these new vaccines. And then contemplate the dawn to come — not just its first rays in the coming months but also the bright light of future years and decades. It looks increasingly plausible that the same weapons we’ll use to defeat Covid-19 can also vanquish even grimmer reapers — including cancer, which kills almost 10 million people a year.The most promising Covid vaccines use nucleic acids called messenger RNA, or mRNA. One vaccine comes from the German firm BioNTech SE and its U.S. partner Pfiz...

Yahoo | January 9, 2021

Read More 'CVAC' Stories Here

CVAC Price Returns

1-mo -7.25%
3-mo 110.37%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD 27.33%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8344 seconds.